Robert Alter, MD, John Theurer Cancer Center
Articles by Robert Alter, MD, John Theurer Cancer Center
Incorporating Treatment Advances Into mRCC Management
ByMartin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Robert Alter, MD, John Theurer Cancer Center,Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre,Amishi Y. Shah, MD, MD Anderson Cancer Center,Sandy Srinivas, MBBS, Stanford Cancer Center Expectations regarding the impact of research in metastatic renal cell carcinoma on the use of immunotherapy and targeted agents in routine clinical practice.
Emerging Therapies for Relapsed/Refractory mRCC
ByMartin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Robert Alter, MD, John Theurer Cancer Center,Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre,Amishi Y. Shah, MD, MD Anderson Cancer Center,Sandy Srinivas, MBBS, Stanford Cancer Center Novel strategies being explored in various stages of clinical trials as potential therapies for relapsed/refractory metastatic renal cell carcinoma.
Relapsed/Refractory mRCC: Sequencing Therapy
ByMartin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Robert Alter, MD, John Theurer Cancer Center,Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre,Amishi Y. Shah, MD, MD Anderson Cancer Center,Sandy Srinivas, MBBS, Stanford Cancer Center Considerations for how to approach a patient with metastatic renal cell carcinoma previously treated with ipilimumab and nivolumab, followed by nivolumab maintenance.
Treatment Approaches for Relapsed/Refractory mRCC
ByMartin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Robert Alter, MD, John Theurer Cancer Center,Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre,Amishi Y. Shah, MD, MD Anderson Cancer Center,Sandy Srinivas, MBBS, Stanford Cancer Center An overview of treatment options for previously treated metastatic renal cell carcinoma.
Adjuvant Therapy Approaches for Operable RCC
ByMartin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Robert Alter, MD, John Theurer Cancer Center,Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre,Amishi Y. Shah, MD, MD Anderson Cancer Center,Sandy Srinivas, MBBS, Stanford Cancer Center A summary of current therapies and ongoing investigations of adjuvant therapy for patients with operable renal cell carcinoma.
Therapies Under Investigation for Frontline mRCC
ByMartin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Robert Alter, MD, John Theurer Cancer Center,Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre,Amishi Y. Shah, MD, MD Anderson Cancer Center,Sandy Srinivas, MBBS, Stanford Cancer Center Novel therapies currently being investigated as frontline options for metastatic renal cell carcinoma.
Favorable-Risk mRCC: Treatment Approaches
ByMartin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Robert Alter, MD, John Theurer Cancer Center,Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre,Amishi Y. Shah, MD, MD Anderson Cancer Center,Sandy Srinivas, MBBS, Stanford Cancer Center A panel discussion regarding individual preferences for treating favorable-risk metastatic renal cell carcinoma.
Favorable-Risk mRCC: When to Initiate Therapy
ByMartin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Robert Alter, MD, John Theurer Cancer Center,Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre,Amishi Y. Shah, MD, MD Anderson Cancer Center,Sandy Srinivas, MBBS, Stanford Cancer Center Dr Amishi Y. Shah, of MD Anderson Cancer Center, describes the rationale for active surveillance vs treatment with a novel therapeutic in metastatic renal cell carcinoma.
Intermediate/Poor-Risk mRCC: Treatment Selection
ByMartin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Robert Alter, MD, John Theurer Cancer Center,Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre,Amishi Y. Shah, MD, MD Anderson Cancer Center,Sandy Srinivas, MBBS, Stanford Cancer Center Factors oncologists should consider prior to selecting a novel treatment approach for metastatic renal cell carcinoma.
Intermediate/Poor-Risk mRCC: I-O/I-O Vs I-O/TKI Therapy
ByMartin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Robert Alter, MD, John Theurer Cancer Center,Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre,Amishi Y. Shah, MD, MD Anderson Cancer Center,Sandy Srinivas, MBBS, Stanford Cancer Center Variables that impact one’s decision to treat metastatic renal cell carcinoma with an immunotherapy-based regimen that includes a targeted agent vs additional immunotherapy.
I-O/TKI Regimens for Metastatic RCC: Dosing Strategies
ByMartin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Robert Alter, MD, John Theurer Cancer Center,Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre,Amishi Y. Shah, MD, MD Anderson Cancer Center,Sandy Srinivas, MBBS, Stanford Cancer Center Recommendations for dosing targeted therapy-immunotherapy combinations used to treat patients with metastatic renal cell carcinoma.
The CLEAR Trial in Metastatic RCC
ByMartin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Robert Alter, MD, John Theurer Cancer Center,Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre,Amishi Y. Shah, MD, MD Anderson Cancer Center,Sandy Srinivas, MBBS, Stanford Cancer Center Characteristics that distinguish the CLEAR trial of lenvatinib plus pembrolizumab as frontline therapy for metastatic renal cell carcinoma from other pivotal trials of immunotherapy plus tyrosine kinase inhibitors.
Frontline Metastatic RCC: Nivolumab Plus Cabozantinib
ByMartin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Robert Alter, MD, John Theurer Cancer Center,Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre,Amishi Y. Shah, MD, MD Anderson Cancer Center,Sandy Srinivas, MBBS, Stanford Cancer Center Robert S. Alter, MD, provides key takeaways from the CheckMate 9ER study of nivolumab plus cabozantinib as frontline therapy for patients with metastatic renal cell carcinoma.
Frontline Metastatic RCC: Pembrolizumab Plus Axitinib
ByMartin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Robert Alter, MD, John Theurer Cancer Center,Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre,Amishi Y. Shah, MD, MD Anderson Cancer Center,Sandy Srinivas, MBBS, Stanford Cancer Center Thomas Powles, MD, MBBS, MRCP, describes the KEYNOTE-426 trial in frontline metastatic renal cell carcinoma and comments on the use of pembrolizumab plus axitinib for appropriate patients.
Frontline Metastatic RCC: Nivolumab Plus Ipilimumab
ByMartin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Robert Alter, MD, John Theurer Cancer Center,Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre,Amishi Y. Shah, MD, MD Anderson Cancer Center,Sandy Srinivas, MBBS, Stanford Cancer Center Amishi Y. Shah, MD, comments on the significance of updated survival data revealed by the CheckMate 214 study using the combination of ipilimumab plus nivolumab as frontline therapy for metastatic renal cell carcinoma.
Frontline Treatment Advances in Metastatic RCC
ByMartin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Robert Alter, MD, John Theurer Cancer Center,Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre,Amishi Y. Shah, MD, MD Anderson Cancer Center,Sandy Srinivas, MBBS, Stanford Cancer Center Dr. Sandy Srinivas comments on treatment approaches for frontline metastatic renal cell carcinoma based on the emergence of novel combination regimens that introduce immunotherapy.
Series Wrap-up: Novel Therapies for mRCC
BySumanta Kumar Pal, MD, City of Hope,Robert Alter, MD, John Theurer Cancer Center,David F. McDermott, MD, Dana Farber Harvard Cancer Center,Tian Zhang, MD, Duke Cancer Center,Bradley McGregor, MD, Dana-Farber Cancer Institute,Thomas E. Hutson, DO, PharmD, Texas Oncology A panel of expert oncologists who manage patients with renal cell carcinoma share enthusiasm over the use of newer novel-based treatment approaches for metastatic disease.
Second-Line Treatment Approaches for Metastatic RCC
BySumanta Kumar Pal, MD, City of Hope,Robert Alter, MD, John Theurer Cancer Center,David F. McDermott, MD, Dana Farber Harvard Cancer Center,Tian Zhang, MD, Duke Cancer Center,Bradley McGregor, MD, Dana-Farber Cancer Institute,Thomas E. Hutson, DO, PharmD, Texas Oncology A brief discussion on current second-line treatment options available to patients with metastatic renal cell carcinoma previously treated with a novel-based regimen.
Biomarker Development in mRCC
BySumanta Kumar Pal, MD, City of Hope,Robert Alter, MD, John Theurer Cancer Center,David F. McDermott, MD, Dana Farber Harvard Cancer Center,Tian Zhang, MD, Duke Cancer Center,Bradley McGregor, MD, Dana-Farber Cancer Institute,Thomas E. Hutson, DO, PharmD, Texas Oncology The significance of studying predictive biomarkers to help oncologists identify mechanisms of resistance to immunotherapy agents in metastatic renal cell carcinoma prior to initiating therapy.
mRCC Treatment: Novel-Based Approaches on the Horizon
BySumanta Kumar Pal, MD, City of Hope,Robert Alter, MD, John Theurer Cancer Center,David F. McDermott, MD, Dana Farber Harvard Cancer Center,Tian Zhang, MD, Duke Cancer Center,Bradley McGregor, MD, Dana-Farber Cancer Institute,Thomas E. Hutson, DO, PharmD, Texas Oncology An overview of novel-based treatment strategies and biomarkers that are currently under investigation to help address current unknowns when treating patients with metastatic renal cell carcinoma.
Frontline mRCC: I-O/TKI Treatment Regimens
BySumanta Kumar Pal, MD, City of Hope,Robert Alter, MD, John Theurer Cancer Center,David F. McDermott, MD, Dana Farber Harvard Cancer Center,Tian Zhang, MD, Duke Cancer Center,Bradley McGregor, MD, Dana-Farber Cancer Institute,Thomas E. Hutson, DO, PharmD, Texas Oncology Limitations of current data surrounding the appropriate use of immunotherapy plus a tyrosine kinase inhibitor as frontline therapy for patients with metastatic renal cell carcinoma and current recommendations for selecting an appropriate combination regimen.
Lenvatinib Plus Pembrolizumab or Everolimus for mRCC
BySumanta Kumar Pal, MD, City of Hope,Robert Alter, MD, John Theurer Cancer Center,David F. McDermott, MD, Dana Farber Harvard Cancer Center,Tian Zhang, MD, Duke Cancer Center,Bradley McGregor, MD, Dana-Farber Cancer Institute,Thomas E. Hutson, DO, PharmD, Texas Oncology Based on data demonstrated by the recent CLEAR study in metastatic renal cell carcinoma, oncologists comment on decisions for using lenvatinib plus pembrolizumab vs lenvatinib plus everolimus.
The CLEAR Study in mRCC
BySumanta Kumar Pal, MD, City of Hope,Robert Alter, MD, John Theurer Cancer Center,David F. McDermott, MD, Dana Farber Harvard Cancer Center,Tian Zhang, MD, Duke Cancer Center,Bradley McGregor, MD, Dana-Farber Cancer Institute,Thomas E. Hutson, DO, PharmD, Texas Oncology Robert S. Alter, MD, of the John Theurer Cancer Center, highlights key data revealed by the phase 3 CLEAR study in metastatic renal cell carcinoma.
PD-1 Vs PD-L1 Inhibition for Frontline mRCC
BySumanta Kumar Pal, MD, City of Hope,Robert Alter, MD, John Theurer Cancer Center,David F. McDermott, MD, Dana Farber Harvard Cancer Center,Tian Zhang, MD, Duke Cancer Center,Bradley McGregor, MD, Dana-Farber Cancer Institute,Thomas E. Hutson, DO, PharmD, Texas Oncology A panel of oncologists discuss the appropriateness for using PD-1 inhibitors versus PD-L1 inhibitors as frontline treatment for metastatic renal cell carcinoma.
Frontline Treatment for mRCC: Dose Adjustments/Discontinuation
BySumanta Kumar Pal, MD, City of Hope,Robert Alter, MD, John Theurer Cancer Center,David F. McDermott, MD, Dana Farber Harvard Cancer Center,Tian Zhang, MD, Duke Cancer Center,Bradley McGregor, MD, Dana-Farber Cancer Institute,Thomas E. Hutson, DO, PharmD, Texas Oncology Advice for appropriately dosing newer novel-based strategies used to treat metastatic renal cell carcinoma and best practices to help community oncologists avoid drug discontinuations.
Frontline Therapy for mRCC: Assessing Quality of Life
BySumanta Kumar Pal, MD, City of Hope,Robert Alter, MD, John Theurer Cancer Center,David F. McDermott, MD, Dana Farber Harvard Cancer Center,Tian Zhang, MD, Duke Cancer Center,Bradley McGregor, MD, Dana-Farber Cancer Institute,Thomas E. Hutson, DO, PharmD, Texas Oncology Expert oncologists debate the significance of using quality of life as a metric when assessing patients’ responses to therapy for metastatic renal cell carcinoma.
The CheckMate 9ER Study in mRCC
BySumanta Kumar Pal, MD, City of Hope,Robert Alter, MD, John Theurer Cancer Center,David F. McDermott, MD, Dana Farber Harvard Cancer Center,Tian Zhang, MD, Duke Cancer Center,Bradley McGregor, MD, Dana-Farber Cancer Institute,Thomas E. Hutson, DO, PharmD, Texas Oncology Takeaways of the CheckMate 9ER trial of nivolumab plus cabozantinib vs sunitinib in previously untreated metastatic renal cell carcinoma.
Novel Strategies for Intermediate-/Poor-Risk mRCC: Optimizing Therapy
BySumanta Kumar Pal, MD, City of Hope,Robert Alter, MD, John Theurer Cancer Center,David F. McDermott, MD, Dana Farber Harvard Cancer Center,Tian Zhang, MD, Duke Cancer Center,Bradley McGregor, MD, Dana-Farber Cancer Institute,Thomas E. Hutson, DO, PharmD, Texas Oncology Drs Bradley A. McGregor and David F. McDermott comment on best approaches for selecting and optimizing treatment with novel combination regimens to manage patients with intermediate- or poor-risk metastatic renal cell carcinoma.
Lenvatinib-Based Combinations for Intermediate-/Poor-Risk mRCC
BySumanta Kumar Pal, MD, City of Hope,Robert Alter, MD, John Theurer Cancer Center,David F. McDermott, MD, Dana Farber Harvard Cancer Center,Tian Zhang, MD, Duke Cancer Center,Bradley McGregor, MD, Dana-Farber Cancer Institute,Thomas E. Hutson, DO, PharmD, Texas Oncology Thomas E. Hutson, DO, PharmD, of Texas Oncology, reacts to results demonstrated by the CLEAR study of lenvatinib in combination with pembrolizumab or everolimus for the treatment of metastatic renal cell carcinoma and discusses best practices for educating community oncologists on dosing with lenvatinib.
Frontline Treatment for Intermediate/Poor-Risk mRCC
BySumanta Kumar Pal, MD, City of Hope,Robert Alter, MD, John Theurer Cancer Center,David F. McDermott, MD, Dana Farber Harvard Cancer Center,Tian Zhang, MD, Duke Cancer Center,Bradley McGregor, MD, Dana-Farber Cancer Institute,Thomas E. Hutson, DO, PharmD, Texas Oncology Considerations for evolving from using single-agent therapy to combination approaches to treat intermediate or poor-risk metastatic renal cell carcinoma based on more recent data demonstrated in clinical trials.
The CLEAR Study in mRCC
Adjuvant Therapy Approaches for Operable RCC
Frontline Metastatic RCC: Nivolumab Plus Cabozantinib
Frontline mRCC: I-O/TKI Treatment Regimens
Lenvatinib Plus Pembrolizumab or Everolimus for mRCC
Frontline Metastatic RCC: Pembrolizumab Plus Axitinib